B
Bruce A. Ellsworth
Researcher at Bristol-Myers Squibb
Publications - 57
Citations - 2159
Bruce A. Ellsworth is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Chemistry & In vivo. The author has an hindex of 19, co-authored 50 publications receiving 2026 citations. Previous affiliations of Bruce A. Ellsworth include Calvin College.
Papers
More filters
Journal ArticleDOI
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Wei Meng,Bruce A. Ellsworth,Alexandra A. Nirschl,P.J. McCann,Manorama Patel,Ravindar N. Girotra,Gang Wu,Philip M. Sher,Eamonn P. Morrison,Scott A. Biller,Robert Zahler,Prashant P. Deshpande,Annie Pullockaran,Deborah Hagan,Nathan Morgan,Joseph R. Taylor,Mary T. Obermeier,William G. Humphreys,Ashish Khanna,Lorell Discenza,James G. Robertson,Aiying Wang,Songping Han,John R. Wetterau,Evan B. Janovitz,Oliver P. Flint,Jean M. Whaley,William N. Washburn +27 more
TL;DR: The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats.
Patent
C-aryl glucoside SGLT2 inhibitors and method
TL;DR: In this article, an SGLT2 inhibiting compound is provided having the formula having the chemical structure, and a method is also provided for treating diabetes and related diseases employing an sGLT 2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
Patent
C-aryl glucoside SGLT2 inhibitors
TL;DR: In this paper, a method for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
Journal ArticleDOI
In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
Mary T. Obermeier,Ming Yao,Ashish Khanna,Barry Koplowitz,Mingshe Zhu,Wenying Li,Bernard J. Komoroski,Sreeneeranj Kasichayanula,Lorell Discenza,William N. Washburn,Wei Meng,Bruce A. Ellsworth,Jean M. Whaley,William G. Humphreys +13 more
TL;DR: Pharmacokinetic parameters for dapagliflozin in preclinical species revealed a compound with adequate oral exposure, clearance, and elimination half-life, consistent with the potential for single daily dosing in humans.
Patent
Methods of producing c-aryl glucoside sglt2 inhibitors
Prashant P. Deshpande,Bruce A. Ellsworth,Janak Singh,Theodor Denzel,Chiajen Lai,Gerard A. Crispino,Michael E. Randazzo,Jack Z. Gougoutas +7 more
TL;DR: In this paper, a method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases is presented. But this method requires the use of amino acid complex forming reagents.